Tunisian Pharmaceutical Company Unimed SA Reports Notable Improvement in Financial Results for First Half of 2025
The Tunisian pharmaceutical company Unimed SA has recorded a significant improvement in its financial results for the first half of 2025. Its revenue reached 72.3 million dinars as of June 30, 2025, compared to 66.2 million dinars a year earlier, mainly driven by the growth of local sales. The latter totaled 50.5 million dinars, while export sales slightly decreased to 21.7 million dinars.
Key Financial Highlights
- Revenue: 72.3 million dinars (up from 66.2 million dinars in the first half of 2024)
- Local sales: 50.5 million dinars
- Export sales: 21.7 million dinars (down from the previous year)
The company's net income for the period showed a significant increase, reaching 10.4 million dinars compared to 7.5 million dinars as of June 30, 2024. The earnings per share rose from 0.236 to 0.325 dinars. This improvement can be attributed to the increase in revenue and investment income, which jumped from 41,000 dinars to over 611,000 dinars.
Balance Sheet and Governance
On the balance sheet side, equity has substantially increased to 123.1 million dinars as of June 30, 2025, compared to 112.7 million dinars at the end of 2024, reflecting the effect of realized profits. However, cash reserves have slightly decreased, with a decline in liquidity from 20.9 to 19.8 million dinars. Supplier debt has significantly decreased, while provisions for risks have increased, reflecting the consideration of new potential disputes.
Notable events during the period include:
- The General Assembly validated the distribution of 18.2 million dinars in dividends
- The company contracted a loan of 500,000 dinars from Amen Bank
- Changes in governance: Mahjoub El Ouni was appointed Chairman of the Board of Directors, and Rached Azaiez was appointed General Manager
Challenges and Outlook
The auditors have expressed a reservation regarding Unimed's participation in Promochimica, a company in difficulty whose financial statements have not been finalized since 2017. Additionally, the company is subject to an in-depth tax audit covering the period 2020-2023, the impact of which remains uncertain.
Despite these points of vigilance, Unimed maintains a solid financial position and confirms its ability to generate increasing profits, supported by the dynamics of the Tunisian market.
